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Left ventricular (LV) function is among the most important
determinants of prognosis in patients with coronary artery
disease (CAD). It is well established that patients with
impaired LV systolic function represent a high risk group
with significantly greater annual mortality than those with
preserved LV function, and that survival rates decline in
proportion to the severity of LV dysfunction (1,2). The
growing number of patients with ischemic LV dysfunction
contributes importantly to the increasing morbidity and
mortality of heart failure in the U. S. (3).
Along with the advances in surgical and percutaneous
myocardial revascularization that have occurred during the
past two decades, numerous studies have demonstrated that
LV dysfunction in many patients is a potentially reversible
phenomenon, related to myocardial stunning, myocardial
hibernation or a combination of these two pathophysiologic
processes, and in these patients LV function may improve
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substantially, and even normalize, after revascularization
(4–8). As many as 40% of patients undergoing coronary
artery bypass surgery with preoperative LV dysfunction
manifest a significant increase in LV ejection fraction when
evaluated several months after operation (9,10).
The likelihood that segmental and global ventricular
function will improve after revascularization can be ascer-
tained using imaging methods that provide evidence of
myocardial viability in dysfunctional regions. The methods
with the greatest evidence base for predicting recovery of
ventricular function are those that provide confirmation of
preserved metabolic activity, cell membrane integrity or
contractile reserve in dysfunctional regions, and hence
positron emission tomography (PET), single photon emis-
sion tomography (SPECT) with thallium-201 or
technetium-99m perfusion tracers and low dose dobutamine
stress echocardiography (DSE) have emerged as accurate
and accepted methods for viability assessment (8,11–15).
Recent data indicate that contrast-enhanced magnetic res-
onance imaging also holds great promise in this arena (16).
The predictive accuracies vary considerably among the
various studies, related in part to methodologic differences,
patient selection factors and timing of the repeat evaluations
after revascularization, but in general PET and SPECT
have higher sensitivity (with greater negative predictive
value) and DSE has higher specificity (with greater positive
predictive value) regarding improved wall motion and in-
creased ejection fraction after revascularization (11,13,15).
A few studies have demonstrated the clinical relevance of
these findings by showing that enhanced LV function with
revascularization translates into symptomatic benefit in
patients with preoperative heart failure symptoms (17–19),
but an unsettled issue of greater clinical relevance is whether
revascularization of viable but dysfunctional myocardium
results in an improvement in survival. There have been a
number of retrospective analyses, each involving relatively
small numbers of patients, that have addressed the prognos-
tic implications of viability testing in patients with CAD
and LV dysfunction, and these studies are summarized
masterfully by Allman et al. (20) in this issue of the Journal.
The meta-analysis of these data by Allman et al. (20)
demonstrates significant differences in survival depending
on the presence or absence of myocardial viability and, in
patients with dysfunctional but viable myocardium, striking
differences in outcome between patients treated medically
and those treated with revascularization.
There are several unsettled issues regarding myocardial
viability and prognosis, such as: 1) whether the outcome of
patients with LV dysfunction and viable myocardium differs
between those treated with medical therapy versus those
undergoing revascularization; 2) whether assessment of
viable myocardium improves the selection of patients for
revascularization; and 3) whether improved outcomes after
revascularization are related to the improvement in LV
function. The first two of these questions are addressed by
the many studies included in the analysis of Allman et al.
(20).
Does revascularization improve survival of patients with
viable myocardium compared to the results of medical
therapy? Although the data addressing this issue have
major limitations, as indicated in the following text, all of
the studies summarized by Allman et al. (20) provide a
comforting degree of consistency and unanimity. In patients
with myocardial viability included in this analysis, the
annual mortality was significantly lower in those treated
with revascularization (3.2%) than those treated medically
(16%). This trend was observed uniformly in all of the
studies, independent of the method used to identify dys-
functional but viable myocardium. Moreover, the magni-
tude of the improvement in outcome with revascularization
in these patients did not depend on whether the evidence of
viable myocardium was provided by PET, SPECT or DSE
(20). Thus, although these methods appear to differ with
respect to prediction of improvement in LV function
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(11,13,15), they appear to be equivalent in identifying a
high risk group of patients in whom survival is enhanced by
revascularization.
Does viability assessment improve selection of patients
with LV function for revascularization? If revasculariza-
tion improves outcome of patients with LV dysfunction and
viable myocardium, as suggested in the preceding text, one
might argue that revascularization should be considered in
all patients with ischemic cardiomyopathy, whether or not
there is evidence of viable myocardium in the regions to be
revascularized. Data from several nonrandomized surgical
databases (1,21) do suggest that the incremental benefit of
surgery over medical therapy is greatest in patients with
severe LV dysfunction—the group in whom the operative
mortality is also the highest. Although the studies cited by
Allman et al. (20) are less consistent regarding this issue
than the uniformity of data regarding the first question, the
summed experience indicates a significantly worse outcome
in patients undergoing revascularization in whom there is
minimal or no evidence of viable myocardium compared to
that of patients with viable myocardium. In patients under-
going revascularization, the annual mortality rate was 3.2%
in those with viable myocardium compared to 7.7% in those
without viable myocardium. In several of these studies
(19,22,23), the perioperative mortality rates were also im-
pressively high in those without myocardial viability (rough-
ly 10%) and negligible in those with viability. Conversely,
the data of Allman et al. (20) also indicate that it is not
necessarily wrong to recommend revascularization in pa-
tients with minimal evidence of myocardial viability, as the
outcome with revascularization is not significantly worse
than that following medical therapy. Management decisions
in this latter subgroup clearly need to be made on a
case-by-case basis, factoring in other considerations such as
age, coronary anatomy and comorbidities.
Taken together, these results of the Allman et al. meta-
analysis (20) represent powerful arguments in favor of
noninvasive evaluation of myocardial viability to identify the
most appropriate candidates for myocardial revasculariza-
tion among patients with CAD and LV dysfunction.
Hence, this analysis of the current literature represents an
important step forward by providing a framework upon
which management decisions can be made. However, there
are a number of important limitations of the current
evidence base that should also be addressed in order to place
these results in proper perspective.
Limitations of the available data. To my knowledge,
there are no prospectively designed trials, randomized or
otherwise, evaluating either the outcome of patients with
severe LV dysfunction (ejection fractions 35%) treated
with medical therapy versus revascularization or the role of
noninvasive testing in determining the most suitable candi-
dates for revascularization. All of the studies in this area,
including those cited by Allman et al. (20) and those
published after the closure of their database in August 1999
(24,25), represent small retrospective, observational series of
patients treated medically or with revascularization. Under
these circumstances, one cannot ignore the distinct potential
for important patient selection biases, related to symptoms,
LV function and angiographic severity of CAD. Allman et
al. (20) correctly identify this as a weakness of their analysis.
Allman et al. (20) are also cognizant of several other
limitations. None of the PET, SPECT or DSE analyses
were standardized among the many studies, and the criteria
for determining the presence or absence of viable myocar-
dium differed considerably. In some series, the criteria for
viability was based on inducible myocardial ischemia,
whereas in others it was based on PET or SPECT data
obtained only at rest or with DSE data obtained only at low
doses of dobutamine. Moreover, the binary grouping of
patients as having “viable” versus “nonviable” myocardium
oversimplifies the complex, inter-related continua of sever-
ity of LV dysfunction, extent and severity of inducible
ischemia and magnitude of dysfunctional but viable myo-
cardium. A meta-analysis of these disparate retrospective
studies cannot possibly account for these intricate multiple
factors. Medical therapy was not standardized, and in many
studies was not described adequately to determine whether
more aggressive adherence to current guidelines of treat-
ment and secondary prevention might have improved out-
come in those treated medically. Severity of angina and
heart failure symptoms were not reported in many of the
series, leaving open the possibility that the overall pooled
patient population was highly heterogeneous. Finally, as
noted by Allman et al. (20), there is a surprising lack of data
addressing the link, if any, between improved LV function
after revascularization and improvement in survival. The
two studies that have focused on this question reached
totally disparate conclusions, one linking outcome with
improvement in function and the other reporting no rela-
tion between changes in ejection fraction and survival after
revascularization (19,26).
Two additional variables that complicate the full inter-
pretation of the current data relate to the type and com-
pleteness of myocardial revascularization. The relative ben-
efits of coronary bypass surgery and percutaneous coronary
intervention have not been addressed, and the grouping
together of patients receiving percutaneous intervention
with those receiving surgery in some studies creates a further
degree of patient heterogeneity. Finally, there is a lack of
postrevascularization angiographic or stress imaging data in
the vast majority of studies to determine success and
completeness of revascularization.
Limitations of meta-analyses. In addition to the afore-
mentioned limitations, there are well-recognized problems
associated with the use of meta-analyses (27), especially
when applied to a nonuniform group of small, retrospective
clinical series. Roughly one third of the results of meta-
analyses cannot be confirmed when subsequently tested with
a randomized controlled clinical trial (28), and often two
meta-analyses by two different groups of investigators with
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access to the same literature arrive at conclusions that are
contradictory (27).
Such general concerns are applicable to the Allman et al.
meta-analysis (20), and there are also more specific con-
cerns. Although four subgroups of patients are identified in
the meta-analysis, most of the 24 viability studies cited by
the authors did not include patients in all four of these
subgroups and evaluated outcome in only one or two
subgroups. For example, of the six studies using thallium-
201 SPECT, only one included patients in all four sub-
groups (29). The other five thallium studies examined
outcome in only two of the patient subgroups: two studies
examined the results of medical therapy versus revascular-
ization in patients with viable myocardium (30,31), two
examined the results of medical therapy in patients with
viable versus nonviable myocardium (32,33) and one exam-
ined the results of revascularization in patients with viable
versus nonviable myocardium (22). Thus, for direct com-
parison of the results of revascularization versus medical
therapy in patients with viable myocardium, only three
thallium studies contribute information on a total of 243
patients (29–31), and for direct comparison of the outcome
of patients undergoing revascularization with viable versus
nonviable myocardium, only two thallium studies contribute
information on a total of only 164 patients (22,29).
Similar issues pertain to the PET and DSE data, as well
as the SPECT data. Only 12 of the 24 studies in the Allman
et al. meta-analysis (20) directly compared the results of a
medical versus a revascularization strategy in patients with
viable myocardium, involving a total of 1,008 patients.
Similarly, only 11 of the 24 studies directly compared the
results of revascularization in patients with viable versus
nonviable myocardium, involving a total of 867 patients.
Need for prospective randomized trials. Clearly, a large
prospective, randomized, controlled clinical trial is necessary
to fully address the role of revascularization in the manage-
ment of patients with ischemic cardiomyopathy who do not
have angina, as well as the role of viability testing in the
decision-making process. One such randomized trial, Sur-
gical Treatment for Ischemic Heart Failure (STICH),
which is sponsored by the National Heart, Lung and Blood
Institute, will begin enrolling patients in 2002. It will be
over six years before the results of STICH are available,
however, and in the interim physicians caring for patients
with CAD and LV dysfunction must continue to base
management decisions on the available data. These data, as
summarized by Allman et al. (20), strongly suggest that the
differentiation of viable from nonviable myocardium is a
relevant diagnostic issue in patients being considered for
medical therapy versus myocardial revascularization. While
these procedures are often accompanied by high operative
morbidity and mortality in patients with LV dysfunction,
many of whom have already undergone a previous bypass
operation, this is the same population that ultimately may
benefit the most from revascularization. Hence, for the
foreseeable future, until randomized controlled trials are
available, nuclear cardiology and echocardiographic tech-
niques will continue to be called upon in the search for
viable myocardium in patients with ischemic LV dysfunc-
tion and in the selection of patients for revascularization.
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